TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20192896
Drug: No sodium
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No sodium thiosulfate (STS) infusion (Control)
Study: 18462572
Drug: Bulk-forming laxatives
Normalized name: Bulk-forming laxatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk-forming laxatives
Study: 18462572
Drug: Stimulant laxatives
Normalized name: STIMULANT LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant laxatives
Study: 18462572
Drug: Adverse effects
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse effects of treatment
Study: 1991925
Drug: Aztreonam treatment
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam treatment
Study: 2472262
Drug: Pentagastrin infusion
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentagastrin infusion (control)
Study: 17706003
Drug: Safety Control
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety Control (another antipsychotic)
Study: 8872628
Drug: Erythrocyte infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythrocyte infusion
Study: 31074816
Drug: Combined high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined high intake of both vitamins (B6 ≥35 mg/d and B12 ≥20 μg/d)
Study: 14762880
Drug: Concurrent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent and adjuvant chemotherapy
Study: 17413103
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g fat/d (5 g fat/meal)
Study: 17413103
Drug: 29 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29 g fat/d (10 g fat/meal)
Study: 9451466
Drug: 5-month individualized
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-month individualized progressive resistance training programme (moderate intensity, high volume) twice a week
Study: 15621801
Drug: Low IPI
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low IPI and rituximab therapy
Study: 24149079
Drug: AS03(B)-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(B)-adjuvanted vaccine
Study: 19745215
Drug: Nonadjuvanted vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted vaccine
Study: 23880306
Drug: ART according
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART according to national treatment eligibility guidelines
Study: 21793317
Drug: Eleutherococcus senticosus
Normalized name: Eleutherococcus Senticosus Root
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eleutherococcus senticosus (ES) 800 mg/d
Study: 10545552
Drug: iNO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNO at 20 ppm (after initial treatment with 2 ppm)
Study: 21192262
Drug: Cancer vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer vaccines (specific formulations not detailed)
Study: 19333170
Drug: Interlaminar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interlaminar epidural steroid injections (IL ESIs)
Study: 7382535
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (0.5 mg/kg hydralazine)
Study: 11979153
Drug: Gadodiamide at
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide at a dose of 0.1 mmol/kg
Study: 11137267
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg doses at 3-day intervals
Study: 25505191
Drug: Intranasal jasmine
Normalized name: jasmine oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal jasmine flower extract (JFE)
Study: 5307603
Drug: Acetone-killed agar-grown
Normalized name: Agar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetone-killed agar-grown dried vaccine (vaccine K-66)
Study: 10598760
Drug: Azelaic acid
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic acid 20% cream
Study: 7853733
Drug: Carbachol infusion
Normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbachol infusion (19 eyes)
Study: 19381108
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy based on ARBs plus ACE inhibitors
Study: 2798542
Drug: Mecamylamine 2.5
Normalized name: mecamylamine 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine 2.5 mg
Study: 29797911
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with western medicine
Study: 7843425
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received gonadotropin-releasing hormone agonist in follicular phase (flare-up) protocols
Study: 16040714
Drug: Intracoronary L-NMMA
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary L-NMMA plus dobutamine
Study: 7871062
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg
Study: 29045514
Drug: anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 antibody (Ab)
Study: 29150857
Drug: 170 μg
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 170 μg LPP
Study: 29150857
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (70 μg, 170 μg, 370 μg)
Study: 9733503
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P antagonist MK-869
Study: 16943535
Drug: Prostate cancer
Normalized name: Leuprolide Acetate 22.5mg Lyophilisate for suspension for injection [Prostate Cancer] with Diluent, Transfer Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate cancer treatment (surgery, radiotherapy, watchful waiting, hormone therapy)
Study: 25694060
Drug: Imeglimin 1500
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 1500 mg twice daily for 1 week
Study: 27927938
Drug: 1 mA
Normalized name: TRAIL-R1 mAb
DrugBank: Mapatumumab (DB18945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mA cathodal tDCS over the contralesional primary motor cortex for 20 minutes during daily therapy
Study: 11055772
Drug: Betula 30c
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betula 30c tablets
Study: 9463204
Drug: Perioperative corticoid
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative corticoid treatment (CC)
Study: 19926058
Drug: Usual-dose sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Usual-dose sirolimus
Study: 30953467
Drug: Adjuvant hepatic
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy with 6 cycles of floxuridine, starting 4-12 weeks after surgery.
Study: 19169289
Drug: Pegfilgrastim 18
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim 18 mg
Study: 23575220
Drug: Griseofulvin 15
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin 15 mg/kg/day
Study: 19769599
Drug: Low-dose aripiprazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aripiprazole adjunctive to antidepressant treatment (ADT)
Study: 12796831
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron 8 mg twice daily for seven days
Study: 7740627
Drug: REC diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: REC diet (low-fat, 28% of energy, high-fibre, 3.3 g/MJ)
Study: 17916138
Drug: Azimilide 125
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 125 mg daily
Study: 19031218
Drug: Trifolium pratense-derived
Normalized name: Trifolium pratense pollen
DrugBank: Trifolium pratense pollen (DB15530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifolium pratense-derived isoflavones (80 mg red clover isoflavones) daily for 90 days
Study: 17558069
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine 45 g/day for 5 days in addition to standard care (group A)
Study: 1505614
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg tid for 6 days (elderly subjects)
Study: 28089225
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment
Study: 22481427
Drug: MF59-adjuvanted formulations
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted formulations
Study: 10090490
Drug: Concentrated oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated oxytocin plus low-dose vaginal prostaglandin E2 (10 mg q 6 h)
Study: 7788255
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (TCl) 20 mg twice daily
Study: 7788255
Drug: Oxybutynin (Oxy)
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin (Oxy) 5 mg three times daily
Study: 6794592
Drug: Oral disodium
Normalized name: etidronate disodium Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disodium cromoglycate (DSCG)
Study: 19366272
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg/day
Study: 25711955
Drug: Higher-protein (HP)
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-protein (HP) breakfast (32 g protein)
Study: 1103897
Drug: oral application
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral application of AR-DF 26
Study: 20642488
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg i.v.-ibuprofen every 6 hours
Study: 7350203
Drug: Intranasal flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal flunisolide 200 micrograms/day
Study: 18179756
Drug: Intranasal flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal flunisolide
Study: 26852726
Drug: Oral solithromycin
Normalized name: roxithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solithromycin (800 mg on day 1, 400 mg on days 2-5, placebo on days 6-7)
Study: 31749051
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide (FAc) implant
Study: 11052557
Drug: Pill organizer
Normalized name: Ezy Dose Weekly AM/PM Pill Organizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill organizer
Study: 17944770
Drug: Ibandronate 6
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 6 mg intravenous infusion
Study: 24814857
Drug: DFPP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFPP combined with oral methylprednisolone
Study: 26012297
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with azelastine and fluticasone propionate
Study: 3290356
Drug: Ketanserin treatment
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin treatment
Study: 7304485
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (9.0 g/day)
Study: 23021480
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment as usual
Study: 8163050
Drug: Amylin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amylin infusion for 6 hours during postabsorptive and euglycaemic hyperinsulinaemic clamp phases.
Study: 27487463
Drug: Ofloxacin eye
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin eye drops administered the day before IVI (four times)
Study: 17314337
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen of salmeterol plus fluticasone
Study: 19469296
Drug: Morphine 0.5
Normalized name: morphine 0.5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.5 mg/ml + ketamine 0.5 mg/ml (MK-group)
Study: 18489634
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oxycodone/325 mg acetaminophen
Study: 25877710
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium ophthalmic solution 0.1%
Study: 14693783
Drug: Deep sclerectomy
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sclerectomy with collagen implant (DSCI)
Study: 2252531
Drug: Combined azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined azathioprine and thymostimulin administration
Study: 27489178
Drug: Migraine-specific medication
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine-specific medication (MSM)
Study: 15040827
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 or 120 mg/day for 3 years
Study: 31278067
Drug: Epigallocatechin gallate
Normalized name: Epigallocatechin Gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigallocatechin gallate (400 mg capsule, orally once daily for 4 weeks, then twice daily for 4 weeks, then three times daily for 40 weeks)
Study: 20693299
Drug: Paclitaxel (Taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (Taxol) (50 mg/mq) combined with non-pegylated liposomal anthracycline (25 mg/mq)
Study: 20693299
Drug: Docetaxel (Taxotere)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (Taxotere) (30 mg/mq) combined with non-pegylated liposomal anthracycline (25 mg/mq)
Study: 20453635
Drug: Low-dose gemcitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gemcitabine and cisplatin
Study: 29683370
Drug: Bao Khi
Normalized name: SODIUM HYPOCHLORITE 1 mg in 1 L EXTRACORPOREAL LIQUID [QIAN BAO Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bao Khi Khang tablets combined with standard therapeutic protocol (Antimicrobial+Corticosteroids+Bronchodilator+Mucolytic drugs)
Study: 22842201
Drug: Staining solution
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staining solution (coffee) with AccessCrown material
Study: 22842201
Drug: Staining solution
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staining solution (coffee) with Structur2 SC material
Study: 16353041
Drug: Ticlopidine (TIC)
DrugBank: Ticlopidine (DB00208)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticlopidine (TIC) 500 mg BID for 2 days and 250 mg BID for subsequent 5 days
Study: 18284648
Drug: Renzapride 4
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 4 mg/day
Study: 29549598
Drug: Adapalene 0.3%
Normalized name: ADAPALENE 0.3% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.3% gel
Study: 15661475
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation, 60 mg retinol equivalent every 3 months
Study: 795437
Drug: Trasylol (aprotinin)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trasylol (aprotinin) treatment
Study: 27524671
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group with monthly bisphosphonate regimen
Study: 11520368
Drug: Monthly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly regimen
Study: 24888479
Drug: WELLFOCUS PPT
Normalized name: PPT
DrugBank: Podofilox (DB01179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WELLFOCUS PPT (11-session group therapy in addition to treatment as usual)
Study: 11432326
Drug: Flonivin BS
Normalized name: BS-001
DrugBank: BS-001 (DB17415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flonivin BS (Bacillus Subtilis IP 5832), 3 x 2 capsules daily for 7 days
Study: 30389671
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) prescriptions
Study: 26365745
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) withdrawal
Study: 10522184
Drug: Implant-retained overdenture
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained overdenture (IRO-group)
Study: 19496943
Drug: Intraduodenal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal administration of increasing Ac doses (12.5/25/50/100 mg Ac in 50 mL water).
Study: 10378552
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 60 mg daily for 14 days
Study: 26265643
Drug: AREDS formulation
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AREDS formulation followed by ranibizumab
Study: 15108768
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) 2 mg/d
Study: 12064813
Drug: Rufloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin 400 mg/week
Study: 11555505
Drug: Target-flow inspiratory
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target-flow inspiratory muscle training (IMT) at 60 to 70% SIPmax, 30 min daily, 6 days a week for 6 months
Study: 30730438
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy
Study: 25425475
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg intravenously every 4 weeks (Q4W)
Study: 24535482
Drug: 13.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.5 mg hyperbaric bupivacaine with 2 mg preservative-free ketorolac
Study: 15598480
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg OD
Study: 2225410
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg q.d.
Study: 12284145
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 10 mg pessaries
Study: 27630374
Drug: 880µg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 880µg of intravitreal sirolimus administered on days 0, 60, and 120
Study: 12859302
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg i.v.
Study: 18423628
Drug: Intravenous lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lansoprazole (90‐mg bolus followed by 9‐mg/h infusion)
Study: 16324861
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine 0.1 mg kg(‐1) with ketamine 0.15 mg kg(‐1) (group KM)
Study: 18423628
Drug: Intravenous lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lansoprazole
Study: 21810288
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose oat β‐glucan (3·0 g β‐glucan; oats high ‐ OH) in responders
Study: 23816448
Drug: Group psychoeducation
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychoeducation (21 sessions, weekly)
Study: 15482167
Drug: Thymalfasin (Talpha1)
Normalized name: thymalfasin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymalfasin (Talpha1) 1.6 mg twice-weekly for 6 months
Study: 15482167
Drug: Thymalfasin (Talpha1)
Normalized name: thymalfasin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymalfasin (Talpha1) and interferon combination therapy